These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34476341)

  • 1. Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor.
    Jordan JH; D'Agostino RB; Ansley K; Douglas E; Melin S; Sorscher S; Vasu S; Park S; Kotak A; Romitti PA; O'Connell NS; Hundley WG; Thomas A
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34476341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.
    Douglas E; Levine B; Ansari A; Ansley K; Melin S; Park CJ; Richardson K; Hatcher S; D'Agostino RB; Jordan JH; Thomas A
    Clin Breast Cancer; 2024 Jun; 24(4):e289-e296. PubMed ID: 38458842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression.
    Kessler AJ; Patel R; Gallagher EJ; Sheng T; Mendu DR; Tiersten A; Klein P; Bhardwaj AS; Goel A; Sparano JA; Shao T; Fasano J
    Breast Cancer Res Treat; 2024 Oct; 207(3):529-532. PubMed ID: 39110275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
    Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
    Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
    Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
    Chen Y; Zhang R; Yan Y; Li H; Song G
    Breast Cancer Res Treat; 2024 Aug; 206(3):543-550. PubMed ID: 38709374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Chlebowski RT; Pan K; Col NF
    Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy.
    Taranto P; de Brito Sales D; Maluf FC; Guendelmann RAK; de Melo Pompei L; Leal A; Buzaid AC; Schvartsman G
    Breast Cancer Res; 2024 Sep; 26(1):133. PubMed ID: 39285489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Perrone F; De Laurentiis M; De Placido S; Orditura M; Cinieri S; Riccardi F; Ribecco AS; Putzu C; Del Mastro L; Rossi E; Tinessa V; Mosconi AM; Nuzzo F; Di Rella F; Gravina A; Iodice G; Landi G; Pacilio C; Forestieri V; Lauria R; Fabbri A; Ibrahim T; De Maio E; Barni S; Gori S; Simeon V; Arenare L; Daniele G; Piccirillo MC; Normanno N; de Matteis A; Gallo C
    Eur J Cancer; 2019 Sep; 118():178-186. PubMed ID: 31164265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study.
    Thomas A; O'Connell NS; Douglas E; Hatcher S; Park CJ; Dent S; Ansley K; Klem I; Bansal R; Westbrook K; Hundley WG; Bottinor W; Hackney MH; Richardson KM; Sirkisoon SR; D'Agostino RB; Jordan JH
    Am Heart J; 2024 Jan; 267():33-43. PubMed ID: 37890547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
    Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
    Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
    Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
    Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
    Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.